KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Cash from Financing Activities (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Cash from Financing Activities for 4 consecutive years, with -$632000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Cash from Financing Activities fell 100.65% year-over-year to -$632000.0, compared with a TTM value of -$3.2 million through Dec 2023, down 103.37%, and an annual FY2025 reading of $17.8 million, up 1122.14% over the prior year.
  • Cash from Financing Activities was -$632000.0 for Q4 2023 at Ginkgo Bioworks Holdings, down from -$315000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $1.5 billion in Q3 2021 and bottomed at -$11.0 million in Q4 2021.
  • Average Cash from Financing Activities over 4 years is $125.1 million, with a median of -$632000.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities tumbled 5837.1% in 2021, then surged 985.29% in 2022.
  • Year by year, Cash from Financing Activities stood at -$186000.0 in 2020, then crashed by 5837.1% to -$11.0 million in 2021, then soared by 985.29% to $97.8 million in 2022, then plummeted by 100.65% to -$632000.0 in 2023.
  • Business Quant data shows Cash from Financing Activities for DNA at -$632000.0 in Q4 2023, -$315000.0 in Q3 2023, and -$1.4 million in Q2 2023.